Hepion Pharmaceuticals is a clinical stage biopharmaceutical company utilizing AI-POWR™, a platform that integrates artificial intelligence and machine learning to develop targeted therapies for chronic liver diseases such as non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Their lead drug candidate, rencofilstat, is designed to inhibit cyclophilins, aiming to reduce liver fibrosis and tumor burden in patients at risk of severe liver conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic liver diseases, including non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC), affect hundreds of millions worldwide and often lack effective treatment options. Current therapies may not adequately address the underlying mechanisms driving disease progression, such as liver fibrosis and tumor development.
Solution
Hepion Pharmaceuticals is developing targeted therapies for chronic liver diseases by utilizing AI-POWR™, a platform integrating artificial intelligence, machine learning, and deep learning. Their lead drug candidate, rencofilstat, inhibits cyclophilins, proteins involved in multiple disease processes. By inhibiting cyclophilins, rencofilstat aims to reduce liver fibrosis and hepatocellular carcinoma tumor burden. Rencofilstat is currently in Phase 2 clinical development for the treatment of NASH.
Target Audience
The primary target audience includes patients at risk of severe liver conditions, such as NASH, fibrosis, and HCC, as well as healthcare providers specializing in hepatology and related fields.
Features
- AI-POWR™ platform combines Artificial Intelligence, Machine Learning, and Deep Learning to decode disease and develop targeted therapies.
- AI-POWR™ is used to select patients that will respond to Hepion therapies.
- Rencofilstat is a potent inhibitor of cyclophilins.
- Rencofilstat has demonstrated reduction in liver fibrosis in experimental disease models.
- Rencofilstat has demonstrated reduction in hepatocellular carcinoma tumor burden in experimental disease models.